Unibest

Pharmaceutical intermediates

Alectinib Hydrochloride Intermediates

6 pharmaceutical intermediates for Alectinib Hydrochloride. Indication: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms.

提交项目All intermediates

About Alectinib Hydrochloride

Originator
Chugai Pharmaceutical Co., Ltd
Indication
Carcinoma, Non-Small-Cell Lung; Lung Neoplasms
Approved Date
12/11/2015
DS/DP
05/29/2031

Available intermediates

6 intermediates currently listed for Alectinib Hydrochloride. Request specifications, documentation or a quotation for any item below.

Alectinib Hydrochloride intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid1256584-73-2//
tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan-2-yl)-1H-indole-3-carboxylate1256584-75-4//
tert-butyl 6-cyano-2-(2-(4-ethyl-3-iodophenyl)propan -2-yl)-1Hindole-3-carboxylate1256584-75-4//
2-(4-ethyl-3-iodophenyl)-2-Methylpropanoic acid1256584-73-2//
tert-butyl 4-(4-ethyl-3-iodophenyl)-4-methyl-3-oxopentanoate1256584-74-3//
4-(piperidin-4-yl)morpholine53617-35-9//

Other programs under A

AbemaciclibAbrocitinibAcalabrutinibAdagrasibAfatinibAfoxolanerAlfacalcidolAlogliptin/ Trelagliptin

Building toward Alectinib Hydrochloride?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →